100 related articles for article (PubMed ID: 28225558)
1. Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab.
Brown TJ; Sher DJ; Nedzi LA; Hughes RS; Beg MS; Mull J; Sarode VR; Khan SA
Head Neck; 2017 May; 39(5):E69-E71. PubMed ID: 28225558
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of rare cutaneous malignant adnexal tumors of the head and neck in a tertiary care cancer hospital: a case series.
Waqas O; Faisal M; Haider I; Amjad A; Jamshed A; Hussain R
J Med Case Rep; 2017 Mar; 11(1):67. PubMed ID: 28284233
[TBL] [Abstract][Full Text] [Related]
3. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
Krishnamurthy J; Krishnamurty DM; Baker JJ; Zhen W; Lydiatt D; Ganti AK
Head Neck; 2013 Dec; 35(12):E372-5. PubMed ID: 23765450
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
[TBL] [Abstract][Full Text] [Related]
5. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
Ghazali N; Parker L; Settle K; Lubek JE
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
[TBL] [Abstract][Full Text] [Related]
6. Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
Nash JW; Barrett TL; Kies M; Ross MI; Sneige N; Diwan AH; Lazar AJ
J Cutan Pathol; 2007 Jan; 34(1):49-54. PubMed ID: 17214855
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
[TBL] [Abstract][Full Text] [Related]
9. Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.
Asakura H; Takashima H; Mitani M; Haba R; Seo R; Yokoe K; Toyama Y; Ohkawa M
Int J Clin Oncol; 2005 Aug; 10(4):285-8. PubMed ID: 16136377
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Unresectable Local Recurrence of Gastric Cancer Successfully Resected after Pre-Operative Chemotherapy with Trastuzumab].
Okubo S; Takahashi T; Miyazaki Y; Makino T; Kurokawa Y; Yamazaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2094-6. PubMed ID: 26805275
[TBL] [Abstract][Full Text] [Related]
11. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
Shammas RL; Cho EH; Glener AD; Poveromo LP; Mundy LR; Greenup RA; Blackwell KL; Hollenbeck ST
J Am Coll Surg; 2017 Dec; 225(6):731-739.e1. PubMed ID: 28985927
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma.
Shabbir A; Qureshi MA; Mirza T; Khalid AB
J Pak Med Assoc; 2017 Jul; 67(7):1085-1090. PubMed ID: 28770892
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adnexal carcinoma with apocrine differentiation.
Prasad V; Kao WH; Kao GF
Cutis; 2016 Dec; 98(6):E16-E19. PubMed ID: 28099545
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma.
Ch'ng S; Low I; Ng D; Brasch H; Sullivan M; Davis P; Tan ST
Hum Pathol; 2008 Mar; 39(3):344-9. PubMed ID: 18045646
[TBL] [Abstract][Full Text] [Related]
16. Scalp metastasis from esophageal adenocarcinoma: comparative histopathology dictates surgical approach.
Doumit G; Abouhassan W; Piliang MP; Uchin JM; Papay F
Ann Plast Surg; 2013 Jul; 71(1):60-2. PubMed ID: 23407258
[TBL] [Abstract][Full Text] [Related]
17. Cervical metastases of microcystic adnexal carcinoma in an otherwise healthy woman.
Rotter N; Wagner H; Fuchshuber S; Issing WJ
Eur Arch Otorhinolaryngol; 2003 May; 260(5):254-7. PubMed ID: 12750914
[TBL] [Abstract][Full Text] [Related]
18. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.
Saleh K; Saada E; Auger N; Mayache-Badis L; Casiraghi O; Bidault F; Bahleda R; Even C
Oral Oncol; 2019 Apr; 91():129-131. PubMed ID: 30773349
[No Abstract] [Full Text] [Related]
20. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
